Objective: To characterize the secretome of differentiating human preadipocytes using global gene expression profiling. Design: Gene expression was measured using microarrays at days 0, 1, 3, 5, 7 and 10 in primary preadipocytes undergoing adipogenesis (n ¼ 6 independent subjects). Predictive bioinformatic algorithms were employed to identify those differentially expressed genes that code for secreted proteins. Measurements: Gene expression was assessed using microarrays and real-time reverse transcriptase PCR, bioinformatic predictive algorithms were used to identify the secretome of differentiating preadipocytes, and the secretion of the most significant candidates were confirmed at the protein level using western blots or ELISA tests. Gene expression was also assayed in the adipocyte and stroma vascular fraction (SVF) of obese subjects. Results: Microarray analysis identified 33 genes whose expression significantly changed (false discovery rate of 1%) during adipogenesis and code for secreted proteins. Of these genes, 18 are novel candidate adipose tissue 'secretome' genes. Their relative gene expression in adipocyte and SVF of obese subjects revealed that most of these genes are more highly expressed in the SVF. A novel candidate, matrix gla protein (MGP), was upregulated (B30-fold) during adipogenesis, second only to leptin (B50-fold). MGP and another secretome candidate protein, inhibin beta B (INHBB), were detected in the secretion media of adipocytes isolated from adipose tissue explants. Conclusions: Gene expression coupled with predictive bioinformatic algorithms has proved a valid and alternative approach to further define the adipocyte secretome. Many of the novel candidate secretome genes are components of the coagulation and fibrinolytic systems. MGP and INHBB represent new adipokines whose function in adipose tissue remains to be unravelled.
Introduction
Adipose tissue is no longer considered a passive reservoir for storing lipids, but rather as an important organ that influences feeding behaviour, energy metabolism, insulin sensitivity and immunoinflammation via the secretion of peptides and proteins, commonly referred to as adipokines. [1] [2] [3] [4] [5] Although the term 'adipokine' implies factors secreted solely from the adipocyte, this term is often more generally used to describe proteins and peptides secreted from the various cell-types present in adipose tissue, including adipocytes, macrophages, endothelial cells, fibroblasts and leucocytes. 5 The biological activity of adipokines varies widely, where some adipokines have been demonstrated to have a role in the paracrine dialogue between adipocytes and components of the stroma vascular fraction (SVF), whereas others exert endocrine actions on other tissues/organs. 1 Their functions range from influencing differentiation, energy metabolism, lipid uptake and transport, immune response and inflammation, vasculature and neuron development, and the remodelling of the extracellular matrix. 4 Gene expression for many adipokines is differentially regulated in obesity and insulin resistance, and is often accompanied by changes in circulating blood levels. Furthermore, the modified secretion of certain adipokines may actively contribute to the pathogenesis of obesity-related comorbidities. For example, the adiponectin deficiency associated with obesity is considered an independent risk factor for endothelial dysfunction, hypertension, insulin resistance and other cardiovascular complications. 6, 7 In contrast, tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6) and plasminogen activator inhibitor-1 (PAI-1) are upregulated in obesity and contribute to the development of metabolic and vascular disease. 8, 9 The list of human adipokines is constantly growing, and defining their regulation and biological activity are paramount to understanding the perturbed molecular pathways in obesity and its downstream complications. Significant effort, in part thanks to the use of comprehensive profiling technologies such as transcriptomics and proteomics, has recently been made to catalogue all factors secreted from adipose tissue. Several studies have reported the use of proteomic strategies to characterize the adipose tissue secretome. The first proteomic studies used mass spectrometry to examine the media of differentiating 3T3-L1 cells and identified changes in proteins affecting the extracellular matrix, growth regulation and complement system; 10, 11 however, species differences are known to exist for secreted adipokines, as outlined in a review by Wang et al. 4 These mouse studies were followed by others using human cellular models (that is, primary cell culture and tissue explants) which confirmed some of the murine adipocyte secreted proteins and identified other human-specific factors that were related to extracellular matrix, inflammatory, signalling and degradation pathways. [1] [2] [3] 12 While these proteomic studies have ameliorated our understanding of adipocyte biology and more completely characterized the adipose tissue secretome, they suffer from an important technological limitation; principally that the proteome remains a theoretical and currently immeasurable entity. 13, 14 Recent estimates indicate that only 10% of predicted eukaryotic proteins have been identified with proteomics research. 14 Therefore, using alternate methods to characterize the adipose tissue secretome will compliment these protein-based studies and provide additional information regarding the endocrine function of adipose tissue in humans. The present work has coupled gene expression profiling with bioinformatic protein sequence analysis to further define the human adipocyte secretome. Exploiting the fact that the entire human genome can be comprehensively assayed using microarrays, we have studied gene expression during human preadipocyte differentiation and used bioinformatic prediction tools to identify the genes that are both differentially regulated during adipogenesis and code for secreted proteins. Gene expression was also studied in the adipocyte and SVF of adipose tissue from obese subjects to further characterize these novel secretome candidates.
Materials and methods

Isolation of human preadipocytes
Subcutaneous white adipose tissue biopsies were obtained from six non-obese (BMI o30 kg/m 2 ) and young healthy female patients (all under the age of 45) undergoing elective surgery. None of the patients had diabetes or metabolic disorders and none were taking medication. This study was approved by the Ethical Committee of the Hôtel-Dieu hospital (Paris, France). Human preadipocytes were isolated and cultured as described in references. 15, 16 Cells were used at passage 2 to eliminate contamination by non preadipocyte cells, as confirmed by negative staining for macrophage markers (Ham 56 and Mac-1).
Differentiation of human preadipocytes
Preadipocytes were cultured for 24 h in Dulbecco's modified Eagle's medium (DMEM)-10 % fetal bovine serum at a cell density of 10 5 cells per well in 12-well plates. The preadipocytes were then incubated with DMEM/F12 induction medium (final concentration of 50 nM insulin, 100 nM dexamethasone, 0.25 mM IBMX and 100 nM rosiglitazone). After 4 days, the medium was replaced with DMEM/F12 culture medium (final concentration of 50 nM insulin, 100 nM dexamethasone and 100 nM rosiglitazone). The medium was changed every 2 days during 10 days. The following time points were studied: days 0 (corresponding to confluent preadipocytes), 1, 3, 5, 7 and 10. At the indicated times, cells were scraped to prepare total RNA and secretion media was collected. Preadipocytes were specifically left for 24 h in serum-free DMEM/F12 so that the presence of the putative secreted molecules could be verified in the absence of serum contaminants.
Sample preparation and experimental design
Total RNA concentration and quality was confirmed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Massy, France). Total RNA (200 ng) from each sample was amplified and transcribed into fluorescent cRNA using Agilent's Low RNA Input Linear Amplification kit (Agilent Technologies). Six samples were obtained at each time point (days 0, 1, 3, 5, 7 and 10) from independent subjects. Only samples that yielded both high quality and a sufficient quantity of RNA were used. Instead of using a universal reference experimental design, we employed a loop experimental design (for details about this experimental design see references 17, 18 ).
Two sequential time points were hybridized together for both direct (samples 1 and 2 labelled with Cy3 and Cy5 dyes, respectively) and swap (samples 1 and 2 labelled oppositely with Cy5 and Cy3 dyes, respectively) microarrays. Samples were hybridized to Agilent 44K two-channel whole human genome microarrays, which are comprised of over 41 000 unique 60-mer oligonucleotide human sequences and transcripts. Sample preparation, hybridization and microarray washing were performed according to manufacturer's recommendations (Agilent Technologies). Arrays were scanned using a GenePix 4000A Scanner (Axon Instruments-Molecular Devices, Sunnyvale, CA, USA).
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Microarray analysis
A Loess normalization was performed using the Goulphar application 19 on log-transformed microarray data without subtracting the background signal, as previously described. 20 An advantage of using direct and swap microarray pairs is the ability to improve the quality of a dataset by filtering and removing data that are dye sensitive, thereby reducing the number of false positives. For each pair of microarrays, expression data that passed this first filter were averaged per probe so as to have a single expression value per probe per microarray pair. Next, only probes corresponding to known gene IDs for which expression data were available across all microarrays (that is, no missing data) at a given time point during preadipocyte differentiation were considered. Differential gene expression was assessed using the Significance Analysis of Microarrays procedure (available at http:// www-stat.stanford.edu/~tibs/SAM/) with a 1% false discovery rate (FDR). The functional profiling of gene expression data was performed using FunNet (http://www.funnet.info), which has been extensively described elsewhere. 21 A P-value threshold of 0.05, which takes into account tests for multiplicity, was used to identify KEGG biological pathways overrepresented in gene expression data.
Predicting secreted factors
Protein accession numbers were obtained for all differentially expressed genes to use the CBS prediction server programs TargetP 1.1. and SecretomeP 2.0 programs. TargetP is a program that predicts the subcellular location of eukaryotic proteins based on N-terminal sequences 22 and
SecretomeP predicts whether a protein is secreted by the non-classical pathway, that is, no signal peptide detected. 23 SecretomeP was used only to confirm TargetP results. Only genes coding for proteins that were identified as 'secreted' by TargetP were considered in this analysis. Moreover, Anderson et al. 24 compiled a non-redundant list of 1175 proteins identified in plasma by using data from various independent sources (literature and three separate mass spectrometry studies of human blood sera). Crossing our list with this nonredundant list of plasma proteins revealed genes that code for proteins identified in circulation and whose expression changed at some point during adipogenesis.
Microarray validation
Gene expression results were validated using the onechannel Illumina Human-WG6 Expression Beadchip platform for one set of samples corresponding to a complete differentiation time course, that is, all 6 time points (n ¼ 1). Data were normalized and analysed using Agilent GeneSpring GX software (Agilent Technologies). Changes in gene expression were calculated in relation to day 0; therefore 5 analyses were performed (day 1 vs day 0, day 3 vs day 0, day 5 vs day 0, day 7 vs day 0 and day 10 vs day 0) and an arbitrary fold-change cut off of 2 was used to identify differentially expressed genes. A subset of genes was also validated by real-time reverse transcriptase PCR (RT-PCR). Reverse transcription was performed with 0.5 mg of total RNA and random hexamer primers, according to manufacturer's instructions (Promega, Charbonnieres-les-Bains, France). RT-PCR amplification was performed using an ABI 7300 (Applied Biosystems, Foster City, CA, USA) with the following thermal cycling conditions: 2 min at 50 1C, 10 min at 95 1C, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min for denaturation, annealing and elongation. All samples were normalized to 18S gene expression (18S rRNA Control kit; Eurogentec, Seraing, Belgium). Differences in gene expression were assessed using a two-tailed, homoscedastic Student's t-test. Specific primers and probes were designed using Universal ProbeLibrary Assay Design Center by Roche Applied Science (https://www.roche-applied-science.com/sis/rtpcr/upl/acenter. jsp?id ¼ 030000).
Western blot analysis
Surgical adipose tissue samples were separated into adipocyte and SVF, as previously described. 25 An equivalent number of cells (1 Â 10 5 cells) were incubated in 1 ml of endothelial cell basal medium containing 1.0% bovine serum albumin. After 24 h of incubation, the media was collected before being resolved on SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were stained by Ponceau red to verify equal loading and transfer. Membranes were then probed overnight at 4 1C with the primary antibody (purified rabbit anti-human matrix gla protein (MGP) polyclonal antibody (ProteinTech Group, Chicago, IL, USA) and mouse anti-human inhibin beta B (INHBB; Abcam, Cambridge, UK)). Proteins were detected with the enhanced chemiluminescence detection solution (GE Healthcare, Amersham Biosciences, Buckinghamshire, UK) and immediately exposed to X-ray films. Protein cellular extracts (10 ug) from CD31 þ vascular cells and macrophages were used as positive controls for MGP and INHBB, respectively.
Adipocyte versus stroma vascular fraction gene expression
Adipocyte and SVF were prepared as described above. The pooled fractions were created starting from surgical adipose tissue samples obtained from age-matched independent obese female subjects (n ¼ 4, average BMI of 34.6 ± 4.0, average age of 37.4 ± 2.4). Total RNA was extracted from these two fractions and gene expression was measured by RT-PCR using both TAQMAN and Sybr green technologies, as described above.
Results
Global gene expression profiles were analysed to identify the biological processes modulated during the differentiation of Gene expression predicts the adipocyte secretome DM Mutch et al human preadipocytes. The use of a loop experimental design permitted changes in gene expression to be determined in relation to the preceding time point; therefore microarray data were available for five comparisons: day 1 vs day 0, day 3 vs day 1, day 5 vs day 3, day 7 vs day 5 and day 10 vs day 7. Using a loop experimental design, we were able to conclude if the expression of a gene changed constantly during the first 10 days of adipogenesis (that is, consistently increased or decreased at all time points examined) or whether a plateau in expression was reached for a gene.
Using an FDR of 1%, we found that the great majority of changes in gene expression in cultured human preadipocytes occurred within the first three days of differentiation (Table 1) . A global functional overview of the differentially expressed genes in the first 3 days of differentiation was performed to identify those biological pathways that are significantly affected during differentiation (Figure 1 ). In the day 1 vs day 0 analysis, 110 gene probes were upregulated and 412 gene probes were downregulated. The upregulated genes were associated with the following KEGG biological pathways: Metabolism of xenobiotics by cytochrome P450, PPAR signalling, glutathione metabolism and polyunsaturated fatty acid biosynthesis. The downregulated genes were associated with cell cycle and the regulation of actin cytoskeleton. In the day 3 vs day 1 analysis, 213 of the 580 differentially expressed genes were upregulated and 367 were downregulated. The upregulated genes were associated with complement and coagulation cascades and adipocytokine signalling KEGG pathways, whereas the downregulated genes were associated with the cell cycle. The identification of the complement and coagulation cascades and adipocytokine signalling pathways, comprised predominantly of genes known to code for secreted proteins (for example, adipsin, complement component 7, von Willebrand factor, leptin and others), prompted us to use differential gene expression data to predict and characterize the secretome of differentiating human adipocytes.
Two bioinformatic tools were employed to identify differentially expressed genes that code for secreted proteins: TargetP 22 and SecretomeP. 23 TargetP is a program that determines the cellular location (mitochondrial, secreted or other) of a given protein based on conserved signal peptides within the protein sequence. SecretomeP is a predictive algorithm that provides an estimate as to whether a given protein might be secreted through a classical or non-classical pathway. More specifically, SecretomeP examines the sequence of a protein to determine whether a signal peptide is detected or not. For the present work, we focused only on those proteins having signal peptides. 213 genes coding for proteins that are labelled as 'secreted' (identified with TargetP) and subsequently confirmed to have a signal peptide (that is, identified with SecretomeP to be secreted via the classical pathway) were identified across all time points (Table 1) . After accounting for genes identified at multiple time points, 200 of the 213 were unique genes found to code for secreted proteins. Gene expression for the vast majority of these genes (184 of 200) changed during early preadipocyte differentiation and then reached a plateau by day 3 (that is, no longer identified in differential expression analyses after day 3). We next cross-checked our list of genes predicted to code for secreted proteins with the human plasma proteome dataset, compiled by Anderson et al. 24 As such, only genes known to code for proteins found in plasma were considered valid candidates. This led to a significant reduction in the number of genes predicted to code for secreted proteins.
Of the 200 genes identified across all time points during differentiation, only 39 genes (that is, B20%) coded for proteins listed in the human plasma proteome dataset. Microarray validation using an alternate expression-profiling platform (Illumina) confirmed that 33 of these 39 changed significantly at some point during differentiation ( Table 2 ). The expression of 13 genes changed during the early stages of adipogenesis and 4 genes changed during the late stages of adipogenesis, whereas the expression levels for the remaining 16 genes changed at other time points. A subset of these genes (Plau, Plaur, Serpine1, Timp1, Inhbb, Mmp9, Mmp1, Cxcl5, Mgp and Lep) was validated by RT-PCR (data not shown). These 33 genes were considered candidate 'secretome' genes based on the transcriptomic work.
To further understand the contribution of adipocytes to the total expression level of these 33 genes in adipose tissue, we examined gene expression in the adipocyte and SVF of adipose tissue from obese female subjects (n ¼ 4, average BMI of 34.6 ± 4.0, average age of 37.4 ± 2.4). Table 3 reveals that the majority of these 33 genes are enriched in the SVF rather than the mature adipocyte, at least in obese individuals (as indicated by negative fold changes). The most significant Gene expression predicts the adipocyte secretome DM Mutch et al adipocyte-dominant candidate gene, apart from leptin, was amine oxidase copper containing 3 (Aoc3). In obese subjects, Aoc3 was 4.8-fold more highly expressed in adipocytes vs SVF. To ensure that our culture system was suitable for identifying novel secreted factors, we confirmed that leptin was both increased during differentiation and detectable in the secretion media (data not shown). The lack of suitable commercial antibodies optimized for protein analysis of novel secretome candidates was a major limitation in our ability to confirm these gene candidates at the protein level, nevertheless we were able examine the secretion of two genes that were differentially expressed during differentiation and candidate 'secretome' genes: MGP and INHBB. We examined the secretion of these proteins into differentiated preadipocyte media using the aforementioned samples; however, they were not consistently detected most likely due to a combination of interindividual sample differences and low concentrations of secreted proteins. Therefore, we isolated adipocytes and the SVF from adipose tissue explants to detect the two aforementioned candidate 'secretome' genes. Both MGP and INHBB are more highly secreted from adipocytes than cells of the SVF (Figures 2a  and b) . MGP was only detected in the secretion media from isolated adipocytes (Figure 2a) , whereas approximately 90% of the INHBB secreted from adipose tissue comes from adipocytes ( Figure 2b ).
Discussion
Since the discovery of leptin, there has been a significant interest in cataloguing those factors secreted by adipose Gene expression predicts the adipocyte secretome DM Mutch et al tissue. Several studies have used proteomic approaches to comprehensively characterize the secretome of adipocytes and/or adipose tissue; however, it is accepted that current analytical technologies fail to fully capture the entire proteome. 14 As such, alternate methods to characterize the secretome will provide novel and complimentary information concerning the paracrine and endocrine functions of adipocytes and adipose tissue. This study has utilized gene expression profiling coupled with predictive bioinformatic algorithms to identify candidate 'secretome' genes whose expression changes during preadipocyte differentiation, as well as providing further information regarding the expression of these candidates in the adipocyte and SVF of adipose tissue. We find that the 33 genes identified as candidate Gene expression predicts the adipocyte secretome DM Mutch et al secretome genes, of which 18 represent novel molecular targets, are predominantly associated with the coagulation and fibrinolytic systems.
A thorough discussion of the functional analysis of microarray data (Figure 1 ) is beyond the scope of the present work. Briefly, this analysis revealed several expected changes during preadipocyte differentiation, such as increases in PPAR signalling and polyunsaturated fatty acid biosynthesis, and decreases in cell cycle and actin cytoskeleton. Furthermore, the identification of the functional pathway metabolism of xenobiotics by cytochrome P450 is intriguing in light of recent suggestions that environmental lipophilic toxins are stored in adipose tissue and released during weight reduction; 26 thus meriting further study. However, it was the identification of the complement and coagulation cascades and adipocytokine signalling pathways that attracted our principle attention.
Using differential gene expression data coupled with predictive bioinformatic programs and the human plasma proteome database, we were able to further characterize the adipocyte secretome. Thirty-three genes were found to both change expression during adipogenesis (either up-or downregulated) and code for proteins detected in the plasma proteome. Data-mining published literature revealed that 15 of these genes code for proteins already demonstrated to be secreted from adipocytes or adipose tissue (see Table 2 ). The expression of six genes (Cd44, Thbd, Pros1, Apoc1, Srpx and Mgp) has previously been shown to change during adipogenesis; however, these 6 genes and the remaining 12 have not been previously associated with the adipocyte secretome.
Adipose tissue is now recognized as an important source for risk factors that link obesity with cardiovascular disease. Factors known to be secreted from adipose tissue include proinflammatory cytokines (IL-6, TNFa and C-reactive protein) and elements of the haemostatic system. 27, 28 This study revealed that several key factors of the haemostatic system are differentially regulated during adipogenesis. Briefly, haemostasis is a process initiated by coagulation events that lead to the deposition of fibrin at the site of a blood clot, which is eventually degraded by fibrinolysis. 28 The principal players in coagulation and fibrinolytic events are prothrombin and plasminogen, respectively. Thrombin is generated from prothrombin by the tissue factor, and converts fibrinogen to fibrin to produce the clot matrix, which is then degraded by plasmin. Plasmin is derived from plasminogen by tissue plasminogen activator (PLAT) or urokinase (PLAU), a process inhibited by PAI-1. Gene expression corresponding to the three aforementioned enzymes changed during adipogenesis in addition to other important actors in haemostasis, such as von Willebrand factor (vWF), thrombomodulin (THBD), thrombospondin-1 (THBS1), protein S alpha (PROS1), C-type lectin domain family 3, member B (CLEC3B, also known as plasminogen kringle 4-binding protein) and plasminogen activator, urokinase receptor (PLAUR). The expression levels for the majority of these factors, except Clec3b, Vwf and Pros1, were highly decreased during early preadipocyte differentiation and this suppression was maintained throughout adipogenesis. These factors tended to be predominantly expressed 33 and now demonstrate in the present work that it is also primarily secreted from adipocytes in adipose tissue. Although the precise role of this gene in adipocytes is unknown, Sjoberg et al. 33 previously revealed that Inhbb mRNA expression correlates with BMI, waist-to-hip ratio, fasting insulin levels and total cholesterol, suggesting that it may have a role in the metabolic syndrome. Finally, of all these candidate secretome genes, Aoc3 (also known as Ssao/ Vap-1) was the gene most predominantly expressed in the adipocyte fraction. AOC3 is found as both a circulating plasma protein implicated in atherogenesis and as a slightly shorter, membrane-bound form responsible for leucocyte trafficking at sites of inflammation. Circulating AOC3 levels are enhanced in obesity and diabetes, and the shorter membrane-bound form was shown to be released by 3T3-L1 adipocytes and human adipose tissue explants; 34 suggesting an important role both locally and systemically for this enzyme. With time, the roles of these candidate secretome genes in the human will be clarified and their contribution to obesity-related diseases better defined. There are several important points to be considered when interpreting these data. Firstly, several known components of the adipocyte secretome (such as adiponectin and IL-6) were not identified in our dataset because our initial stringent selection criteria imposed that no missing values were observed for a given gene in our microarray dataset. Although it is probable that many more adipocyte genes code for secreted proteins and whose expression levels change during adipogenesis, we preferred to reduce the number of false positives by using only microarray data for which gene expression was consistently detected in all samples at a given time-point. Secondly, although the TargetP bioinformatic prediction program can identify signal peptides that indicate a secreted protein, it cannot distinguish between what is secreted to the extracellular matrix of the adipocyte (but still membrane attached) and what is secreted from the adipocyte into circulation. Thus, although our data identify 18 novel candidate secretome genes that code for proteins found in plasma, it is unknown whether the adipocyte actually contributes to the circulating levels of these gene products or whether these gene products only act locally within adipose tissue. Thirdly, although all of these gene products are found in the Human Plasma Proteome database, our data do not permit us to evaluate to what degree the adipocyte (or adipose tissue) contributes to the circulating plasma levels of these proteins in comparison to other tissues; indeed, it could range from negligible to important. Additionally, the Human Plasma Proteome database lists proteins identified by proteomic approaches in normal healthy subjects, therefore this most likely resulted in an increased stringency for our analyses. Indeed, it is important to consider the analytical limitations associated with proteomics (as previously mentioned), as well as the possibility that the plasma proteome in diseased states may differ from that of the healthy state. Finally, our data concerning MGP reinforce the importance of validating gene expression data at the protein level when studying the adipose tissue secretome. Based on adipocyte vs SVF gene expression results we hypothesized that MGP would be more highly secreted from the SVF; however, we have shown that this is not the case. As such, it is unclear why the Mgp gene is more highly expressed in the SVF. Taken together, further functional studies are needed to fill the existing gaps in our knowledge regarding the biological roles of these novel candidate secretome genes.
In conclusion, we have exploited the fully characterized human genome to identify candidate 'secretome' genes in the both the adipocyte and SVF to compliment previous protein-based work in this domain. As a next step, it will be of interest to study the expression profiles of these candidate 'secretome' genes in the adipocyte and SVF of both obese and lean subjects to determine whether body corpulence affects their adipose tissue expression signature and ultimately, their secretion. The validity of this novel approach was reinforced by the confirmation that MGP and INHBB are novel components of the adipose tissue secretome. The genes that code for proteins not previously found using proteomic strategies correspond to potentially important Gene expression predicts the adipocyte secretome DM Mutch et al players related to the haemostatic system and extracellular matrix, as well as possible (and previously unrecognized) risk factors for obesity-related complications.
